Differential levels of synovial fluid aggrecan aggregate components in experimental osteoarthritis and joint disuse.
The levels of proteoglycan aggregate components (link protein, keratan sulfate epitope, and total sulfated glycosaminoglycan) were determined in the synovial fluid lavages of dogs with experimental osteoarthritis or disuse atrophy. A model of experimental osteoarthritis was created by transection of the anterior cruciate ligament of the right knee; studies were carried out 6 and 12 weeks after surgery. Joint disuse was studied at 4 and 8 weeks after initiation of the disuse. Recovery after disuse also was studied in joints that had 3 weeks of remobilization after 4 or 8 weeks of disuse. Synovial fluid lavages from the right knee joints of untreated animals were used as controls. The concentrations of keratan sulfate epitope, sulfated glycosaminoglycan, and link protein in the synovial fluid lavages at 6 and 12 weeks after transection of the anterior cruciate were elevated compared with the control values. Similar analysis of the fluid after disuse showed that the levels of keratan sulfate epitope and sulfated glycosaminoglycan were increased compared with the control levels and the levels after transection. However, the concentration of link protein in the fluid after disuse was not significantly different from the control level. The levels of keratan sulfate epitope and sulfated glycosaminoglycan in the synovial fluid lavages after disuse with recovery were high, but the levels of link protein remained low. The results indicate that the catabolism of proteoglycan aggregates in articular cartilage during early osteoarthritis and disuse is different. The determination of keratan sulfate epitope in synovial fluid lavages appears to provide a relatively general indication of proteoglycan catabolism, whereas increased levels of link protein may be more indicative of cartilage degeneration.
Ratcliffe
A
A
Department of Orthopaedic Surgery, Columbia University, New York, New York.
Beauvais
P J
PJ
Saed-Nejad
F
F
D053674:Aggrecans; D000704:Analysis of Variance; D000818:Animals; D001857:Bone Matrix / Q000737:chemistry / Q000378:metabolism; D002358:Cartilage, Articular / Q000737:chemistry / Q000378:metabolism / Q000502:physiology; D004195:Disease Models, Animal; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes; D016326:Extracellular Matrix Proteins; D006025:Glycosaminoglycans / Q000032:analysis / Q000378:metabolism; D007592:Joint Diseases / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D007632:Keratan Sulfate / Q000032:analysis / Q000378:metabolism; D007719:Knee Joint / Q000196:embryology / Q000473:pathology / Q000502:physiology; D037181:Lectins, C-Type; D010003:Osteoarthritis / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D011509:Proteoglycans / Q000032:analysis* / Q000378:metabolism; D011863:Radioimmunoassay; D013582:Synovial Fluid / Q000737:chemistry* / Q000378:metabolism
D053674:Aggrecans; D000939:Epitopes; D016326:Extracellular Matrix Proteins; D006025:Glycosaminoglycans; D037181:Lectins, C-Type; D011509:Proteoglycans; D007632:Keratan Sulfate